Virtu Financial LLC Sells 38,086 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)

Virtu Financial LLC decreased its holdings in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 48.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 41,155 shares of the company’s stock after selling 38,086 shares during the quarter. Virtu Financial LLC owned 0.06% of SELLAS Life Sciences Group worth $43,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in SLS. Opus Capital Group LLC raised its stake in shares of SELLAS Life Sciences Group by 5.5% during the 4th quarter. Opus Capital Group LLC now owns 238,500 shares of the company’s stock worth $248,000 after purchasing an additional 12,400 shares during the period. State Street Corp raised its position in SELLAS Life Sciences Group by 30.2% in the third quarter. State Street Corp now owns 174,529 shares of the company’s stock worth $218,000 after acquiring an additional 40,500 shares during the period. XTX Topco Ltd purchased a new position in SELLAS Life Sciences Group in the third quarter valued at about $78,000. Geode Capital Management LLC increased its stake in shares of SELLAS Life Sciences Group by 17.1% during the 3rd quarter. Geode Capital Management LLC now owns 605,191 shares of the company’s stock worth $757,000 after purchasing an additional 88,183 shares during the last quarter. Finally, Brooklyn FI LLC bought a new stake in shares of SELLAS Life Sciences Group in the 4th quarter worth approximately $677,000. Institutional investors and hedge funds own 17.38% of the company’s stock.

SELLAS Life Sciences Group Stock Performance

Shares of NASDAQ SLS opened at $1.09 on Wednesday. SELLAS Life Sciences Group, Inc. has a fifty-two week low of $0.77 and a fifty-two week high of $1.84. The stock has a market cap of $99.02 million, a PE ratio of -1.58 and a beta of 2.43. The stock has a fifty day moving average of $1.23 and a 200-day moving average of $1.17.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. During the same period in the prior year, the business posted ($1.34) EPS. On average, sell-side analysts predict that SELLAS Life Sciences Group, Inc. will post -0.57 EPS for the current year.

SELLAS Life Sciences Group Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.